This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

ATRA in acute promyelocytic leukaemia trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This trial compared disease-free survival and overall survival in patients with previously untreated acute promyelocytic leukaemia who were randomised to ATRA+chemotherapy or chemotherapy alone.

346 patients were randomised to one of two protocols:

  • ATRA induction:
    • ATRA as induction treatment
    • patients in complete remission underwent another cycle of ATRA treatment
    • high dose daunorubicin and cytarabine
    • patients still in complete remission were randomised to maintenance with ATRA or observation

  • chemotherapy induction:
    • daunorubicin and cytarabine induction
    • patients in complete remission had another cycle of chemotherapy
    • high dose daunorubicin and cytarabine
    • patients still in complete remission were randomised to maintenance with ATRA or observation

Results:

  • ATRA and chemotherapy were equally effective as induction agents
  • disease-free survival was higher in regimens containing ATRA
  • overall survival was higher in regimens containing ATRA

Reference:

  • Tallman, MS. et al. (1997). All-trans-retinoic acid in acute promyelocytic leukaemia. New Engl. J. Med. 337, 1021-8.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.